Conference Call with Hester Biosciences Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY25 results Revenue from operations: Rs 819.25 million compared to Rs 792.55 million during Q4FY24, change 3%. Gross Profit Margin: Rs 611.83 million compared to Rs 577.16 million during Q4FY24, change 6%. EBITDA: Rs 135.41 million compared to Rs 205.48 million during Q4FY24, change -34%. EBITDA margin: 17% for Q4FY25. PAT: Rs 15.41 million compared to Rs 63.95 million during Q4FY24, change -76%. PAT margin: 2% for Q4FY25. Result PDF
Pharmaceuticals company Hester Biosciences announced Q3FY25 results Divisional Product Sales: Rs 632.18 million, down 6% YoY from Rs 669.83 million Revenue from Operations: Rs 632.18 million, down 6% YoY from Rs 669.83 million Hester Nepal: Rs 8.09 million, up 2% YoY from Rs 7.91 million Hester Africa: Rs 8.05 million, up 11% YoY from Rs 7.26 million Gross Profit Margin: Rs 435.93 million, down 6% YoY from Rs 463.44 million EBITDA: Rs 138.45 million, up 12% YoY from Rs 123.53 million EBITDA %: 22%, up 4% YoY from 18% PAT: Rs 114.08 million, up 184% YoY from Rs 40.20 million PAT %: 18%, up 12% YoY from 6% EPS: Rs 13.41, up 184% YoY from 4.73 Result PDF
Pharmaceuticals company Hester Biosciences announced Q2FY25 results Revenue from operations: Rs 836.92, compared to Q2FY24 Rs 704.55 change 19%. Consolidated EBITDA: Rs 219.55 million change 15% Q2FY25 Consolidated Divisional Product sales up by 21% & Profit up by 108%. Hester Nepal achieved net profit of Rs 0.29 million in Q2FY25, reversing from a loss of Rs 7.05 million in Q2FY24. The subsidiary fulfilled export orders from government tenders and met domestic vaccine demand, showcasing its growth potential. Hester Nepal remains debt-free with strong cash flows from the quarter. Hester Africa reduced its net loss to Rs 23.67 million in Q2FY25, down from net loss of Rs 49.17 million in Q2FY24. Hester Africa is actively participating in international tenders and meeting trade demands across various African countries, with increasing awareness and demand for vaccines. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q1FY25 results: Q1FY25 Standalone Divisional Product sales up by 37% & Profit up by 30% Q1FY25 Consolidated Divisional Product sales up by 35% & Profit up by 9% The divisional performance has demonstrated growth in the current quarter compared to Q1FY24, with sales increasing by 37%. The overall sales show a decrease of 9% QoQ, primarily attributed to the one-time sales of other pharmaceutical products in Q1FY24. Hester focused on higher-margin products and solutions in Q1FY25, leading to a significant rise in gross profit margin from 57% to 69%. Increased revenue from divisional product sales allowed for better absorption of fixed costs, resulting in a 5% improvement in EBITDA%. Overall absolute PAT increased by 30% and PAT% ratio increased by 3%, reflecting improved operational efficiency. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Hester Biosciences announced Q4FY24 & FY24 results: Financial Highlights: Hester Biosciences reported an increase in standalone revenue by 20% and consolidated revenue by 18% in Q4FY24 compared to the previous year. The audited financial results for Q4 & FY24 show the company's resilience with a recommendation for a dividend of 6 per equity share of Rs 10 each (60%) for FY24, awaiting shareholder approval. The company has reduced its borrowing by 19% and increased cash generated from operations by 28% during the year. Overall gross profit margin in Q4FY24 increased by 1% compared to Q4FY23, primarily due to the increase in the proportion of vaccines from 60% to 75% in Q4FY24. In Q4FY24, EBITDA increased by 14% in alignment with a growth in sales, resulting in a 19% increase in PAT for the quarter. The total borrowings of the Company has reduced by Rs 307.58 million (19%) during the year. The cash generated from operations has increased by Rs 94.50 million (28%) during the year Animal Healthcare Division: The Animal Healthcare division saw a growth of 89% in Q4FY24, driven by sales of Goat Pox vaccine and vaccines for a government immunisation program. Despite regulatory challenges, the Animal Healthcare division has demonstrated the ability to recover and sustain growth. Poultry Healthcare Division: The Poultry Healthcare division achieved a notable growth of 22% in Q4FY24, with a consistent upward trend throughout the year. Strategic introductions of new products and leveraging market opportunities have been instrumental in the division's sales performance. Petcare Division: In Q4FY24, the Petcare division saw a minor decrease in sales from the previous quarter but reported a notable annual growth of 49%. The Petcare division's focus on building a strong foundation and delivering high-quality products is reflected in its substantial growth. Result PDF
Conference Call with Hester Biosciences Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.